- Home
- DTST vs LTRN Comparison
DTST vs LTRN Comparison
Compare DTST & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | LTRN |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 10.0M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DTST | LTRN |
|---|---|---|
| Price | $3.00 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 18.1K | ★ 327.0K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3671.43 | 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,382,929.00 | N/A |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.75 | $0.60 |
| 52 Week High | $5.15 | $4.34 |
Technical Indicators
Market Signals| Indicator | DTST | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 21.85 |
| Support Level | $2.82 | N/A |
| Resistance Level | $3.15 | $1.96 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 17.53 | 18.38 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.